Coyle Financial Counsel’s Gilead Sciences GILD Stock Holding History

Coyle Financial Counsel’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q3	–	Sell	-97	Closed	-$7K	–	141
2018 Q2	$7K	Buy	+97	New	+$6.85K	0.01%	141

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Coyle Financial Counsel's GILD Position: Q3 2018 in Review

Coyle Financial Counsel sold out of Gilead Sciences (GILD) in Q3 2018, closing a stake of 97 shares — an estimated $7K sold.

Coyle Financial Counsel first reported a position in GILD in Q2 2018 and held it in 1 quarter. The position peaked at $7K in Q2 2018. 1,527 funds tracked by Wall St. Rank hold GILD as of Q3 2018.

Coyle Financial Counsel reported no remaining Gilead Sciences position as of Q3 2018 after selling out during the quarter.
Coyle Financial Counsel sold 97 Gilead Sciences shares in Q3 2018, an estimated $7K.
Coyle Financial Counsel first reported a position in Gilead Sciences in Q2 2018 and held it in 1 quarter.
Coyle Financial Counsel's Gilead Sciences position peaked at $7K in Q2 2018.
1,527 funds tracked by Wall St. Rank held Gilead Sciences as of Q3 2018.

Based on Coyle Financial Counsel's 13F filing for Q3 2018, filed 13 Nov 2018.